[go: up one dir, main page]

MA61946B1 - Anticorps capables de se lier à la protéine spike du coronavirus sars-cov-2 - Google Patents

Anticorps capables de se lier à la protéine spike du coronavirus sars-cov-2

Info

Publication number
MA61946B1
MA61946B1 MA61946A MA61946A MA61946B1 MA 61946 B1 MA61946 B1 MA 61946B1 MA 61946 A MA61946 A MA 61946A MA 61946 A MA61946 A MA 61946A MA 61946 B1 MA61946 B1 MA 61946B1
Authority
MA
Morocco
Prior art keywords
cov
binding
spike protein
antibodies capable
coronavirus sars
Prior art date
Application number
MA61946A
Other languages
English (en)
Inventor
Gavin Screaton
Juthathip Mongkolsapaya
Original Assignee
Rqbio Covid Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2202232.1A external-priority patent/GB202202232D0/en
Priority claimed from GBGB2203423.5A external-priority patent/GB202203423D0/en
Priority claimed from GBGB2212470.5A external-priority patent/GB202212470D0/en
Priority claimed from GBGB2214036.2A external-priority patent/GB202214036D0/en
Priority claimed from GBGB2215418.1A external-priority patent/GB202215418D0/en
Priority claimed from GBGB2301959.9A external-priority patent/GB202301959D0/en
Application filed by Rqbio Covid Limited filed Critical Rqbio Covid Limited
Publication of MA61946B1 publication Critical patent/MA61946B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/104—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des anticorps utiles pour la prévention, le traitement et/ou le diagnostic des infections à coronavirus, et des maladies et/ou complications associées aux infections à coronavirus, y compris la COVID-19. En particulier, l'invention concerne des anticorps capables de se lier à la protéine de pointe du coronavirus SARS-CoV-2 et leurs utilisations.
MA61946A 2022-02-18 2023-02-17 Anticorps capables de se lier à la protéine spike du coronavirus sars-cov-2 MA61946B1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB2202232.1A GB202202232D0 (en) 2022-02-18 2022-02-18 Antibodies
GBGB2203423.5A GB202203423D0 (en) 2022-03-11 2022-03-11 Antibodies
GB202206777 2022-05-09
GBGB2212470.5A GB202212470D0 (en) 2022-08-26 2022-08-26 Antibodies
GBGB2214036.2A GB202214036D0 (en) 2022-09-26 2022-09-26 Antibodies
GBGB2215418.1A GB202215418D0 (en) 2022-10-18 2022-10-18 Antibodies
GBGB2301959.9A GB202301959D0 (en) 2023-02-10 2023-02-10 Antibodies
EP23157409.6A EP4230650B1 (fr) 2022-02-18 2023-02-17 Anticorps capables de se lier à la protéine spike du coronavirus sars-cov-2

Publications (1)

Publication Number Publication Date
MA61946B1 true MA61946B1 (fr) 2025-04-30

Family

ID=85283974

Family Applications (1)

Application Number Title Priority Date Filing Date
MA61946A MA61946B1 (fr) 2022-02-18 2023-02-17 Anticorps capables de se lier à la protéine spike du coronavirus sars-cov-2

Country Status (18)

Country Link
US (2) US12030927B2 (fr)
EP (1) EP4230650B1 (fr)
AR (1) AR128564A1 (fr)
CL (1) CL2024002462A1 (fr)
DK (1) DK4230650T3 (fr)
ES (1) ES3012638T3 (fr)
FI (1) FI4230650T3 (fr)
HR (1) HRP20250103T1 (fr)
HU (1) HUE070285T2 (fr)
LT (1) LT4230650T (fr)
MA (1) MA61946B1 (fr)
PL (1) PL4230650T3 (fr)
PT (1) PT4230650T (fr)
RS (1) RS66591B1 (fr)
SI (1) SI4230650T1 (fr)
SM (1) SMT202500056T1 (fr)
TW (1) TW202342510A (fr)
WO (1) WO2023156636A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023518849A (ja) 2020-03-26 2023-05-08 バンダービルト・ユニバーシティ 重症急性呼吸器症候群コロナウイルス２（ＳＡＲＳ－ＣｏＶ－２）に対するヒトモノクローナル抗体
JP2025514858A (ja) 2022-04-29 2025-05-09 アストラゼネカ・ユーケイ・リミテッド ＳＡＲＳ－ＣｏＶ－２抗体、及びその使用方法
GB202304512D0 (en) * 2023-03-28 2023-05-10 Univ Oxford Innovation Ltd Antibodies

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122427A (en) 1976-06-24 1978-10-24 Herbert Karsh Motion monitor
JPS58188433A (ja) 1982-04-28 1983-11-02 アロカ株式会社 超音波診断装置
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0216846B2 (fr) 1985-04-01 1995-04-26 Celltech Limited Lignee cellulaire de myelomes transformee et procede d'expression d'un gene codant un polypeptide eucaryotique employant cette lignee
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5088498A (en) 1988-10-17 1992-02-18 The Board Of Regents Of The University Of Washington Ultrasonic plethysmograph
JPH03151944A (ja) 1989-11-08 1991-06-28 Hitachi Medical Corp パルスドプラ計測装置
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
JPH0767451B2 (ja) 1991-12-24 1995-07-26 アロカ株式会社 超音波組織変位計測装置
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
JPH08507706A (ja) 1993-02-25 1996-08-20 アドバンスト モニターズ ホールディングズ リミテッド 超音波モニター
CA2163345A1 (fr) 1993-06-16 1994-12-22 Susan Adrienne Morgan Anticorps
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5573012A (en) 1994-08-09 1996-11-12 The Regents Of The University Of California Body monitoring and imaging apparatus and method
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
CA2249195A1 (fr) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1141024B1 (fr) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRENANT UNE VARIANTE DE LA REGION Fc DE L'IgG1 HUMAIN
DE19914455B4 (de) 1999-03-30 2005-07-14 Siemens Ag Verfahren zur Bestimmung der Bewegung eines Organs oder Therapiegebiets eines Patienten sowie hierfür geeignetes System
ES2601882T5 (es) 1999-04-09 2021-06-07 Kyowa Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
CA2388245C (fr) 1999-10-19 2012-01-10 Tatsuya Ogawa L'utilisation de cellules de rat adaptess exemptes de serum pour produire de polypeptides heterologues
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
JP2004501642A (ja) 2000-06-28 2004-01-22 グライコフィ，　インコーポレイテッド 改変された糖タンパク質を生成するための方法
HU231090B1 (hu) 2000-10-06 2020-07-28 Kyowa Kirin Co., Ltd. Antitest-kompozíciót termelő sejt
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ATE233517T1 (de) 2000-11-22 2003-03-15 Brainlab Ag Verfahren zur bestimmung der lungenfüllung
EP1355919B1 (fr) 2000-12-12 2010-11-24 MedImmune, LLC Molecules a demi-vies longues, compositions et utilisations de celles-ci
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
EP1539233B1 (fr) 2001-07-12 2011-04-27 FOOTE, Jefferson Anticorps super humanises
EP1423510A4 (fr) 2001-08-03 2005-06-01 Glycart Biotechnology Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
EP1485486B1 (fr) 2002-03-19 2012-11-21 Stichting Dienst Landbouwkundig Onderzoek Optimisation du traitement du glycane chez les plantes
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
GB2396012B (en) 2002-12-03 2006-03-15 Neorad As Respiration monitor
US8814793B2 (en) 2002-12-03 2014-08-26 Neorad As Respiration monitor
NZ582315A (en) 2003-01-22 2011-01-28 Glycart Biotechnology Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
US6932769B2 (en) 2003-05-28 2005-08-23 Delphi Technologies, Inc. Ultrasonic occupant detection and classification system
AR047692A1 (es) 2003-07-10 2006-02-08 Epix Medical Inc Imagenes de blancos estacionarios
KR101264442B1 (ko) 2004-08-31 2013-05-14 유니버시티 오브 워싱톤 협착된 혈관에서 벽 진동을 평가하는 초음파 기술
US20080146911A1 (en) 2004-10-18 2008-06-19 Kabushiki Kaisha Toshiba Respiration Monitoring Apparatus, Respiration Monitoring System, Medical Processing System, Respiration Monitoring Method, And Respiration Monitoring Program
US20060241443A1 (en) 2004-11-22 2006-10-26 Whitmore Willet F Iii Real time ultrasound monitoring of the motion of internal structures during respiration for control of therapy delivery
MX2007013924A (es) 2005-05-09 2008-01-28 Glycart Biotechnology Ag Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc.
US20060285071A1 (en) 2005-06-21 2006-12-21 Bausch & Lomb Incorporated Femtosecond laser micromachining of a contact lens and a contact lens manufactured thereby
JPWO2007032329A1 (ja) 2005-09-14 2009-03-19 パナソニック株式会社 位置追跡方法、位置追跡装置および超音波診断装置
US7884264B2 (en) 2006-01-17 2011-02-08 Biolex Therapeutics, Inc. Compositions and methods for inhibition of fucosyltransferase and xylosyltransferase expression in duckweed plants
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
RU2009116246A (ru) 2006-09-29 2010-11-10 Конинклейке Филипс Электроникс Н.В. (Nl) Способ и устройство для ультразвукового исследования, оставляющее руки свободными
US20090048518A1 (en) 2006-12-10 2009-02-19 Cardio Art Technologies Ltd. Doppler motion sensor apparatus and method of using same
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
CN101855242B (zh) 2007-09-14 2014-07-30 阿迪马布有限责任公司 合理设计的合成抗体文库及其用途
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US10398393B2 (en) 2007-10-02 2019-09-03 Stryker European Holdings I, Llc Dynamic reference method and system for interventional procedures
WO2014152463A1 (fr) 2013-03-15 2014-09-25 Cyberheart, Inc. Appareil et procédé pour le suivi en temps réel de structures tissulaires
WO2009128963A2 (fr) 2008-01-17 2009-10-22 Humab, Llc Anticorps monoclonaux humains à neutralisation croisée dirigés contre sars-cov et procédés d'utilisation de ces derniers
GB2476623B (en) 2008-11-06 2012-11-28 Neorad As Extravasation detection for fluid injection using dopppler ultrasound blood flow measurement
RU2650594C1 (ru) 2009-01-29 2018-04-17 Медиммун, Ллк Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний
US10098572B2 (en) 2009-07-20 2018-10-16 Koninklijke Philips N.V. Method for operating a monitoring system
US20110121996A1 (en) 2009-11-23 2011-05-26 Delphi Technologies, Inc. Method and System for Detecting an Occupant Using Reflected Signals
US20110208060A1 (en) 2010-02-24 2011-08-25 Haase Wayne C Non-contact Biometric Monitor
JP5492606B2 (ja) 2010-03-03 2014-05-14 アズビル株式会社 演算装置、及び演算装置を備えた流量計
GB2479930B (en) 2010-04-29 2017-12-06 Respinor As Coupling an ultrasound probe to the skin
WO2011139718A1 (fr) 2010-05-03 2011-11-10 Genentech, Inc. Compositions et procédés utiles pour la réduction de la viscosité de formulations contenant des protéines
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
PT2603138T (pt) 2010-08-13 2018-02-26 Respiratory Motion Inc Dispositivos e métodos para monitorização de variação respiratória por medição de volumes respiratórios, movimentação e variabilidade
KR101614195B1 (ko) 2011-03-29 2016-04-20 로슈 글리카트 아게 항체 Fc 변이체
US9526476B2 (en) 2011-04-12 2016-12-27 Brigham And Women's Hospital, Inc. System and method for motion tracking using unique ultrasound echo signatures
US20130030285A1 (en) 2011-07-26 2013-01-31 General Electric Company System and method for integrating multiple data sources into an x-ray image referential
US10207072B2 (en) 2011-08-22 2019-02-19 Resmed Limited Ultrasonic welding of fabrics for sleep apnea treatment
JP5950517B2 (ja) 2011-09-02 2016-07-13 キヤノン株式会社 被検体情報取得装置、被検体情報取得方法、及びプログラム
ES2746103T3 (es) 2012-04-30 2020-03-04 Medimmune Llc Moléculas con función efectora reducida y semividas prolongadas, composiciones y usos de las mismas
AU2013260172B2 (en) 2012-05-11 2017-11-23 Medimmune Limited CTLA-4 variants
JP6096459B2 (ja) 2012-10-04 2017-03-15 東芝メディカルシステムズ株式会社 超音波診断装置
US9576357B2 (en) 2013-01-17 2017-02-21 Koninklijke Philips N.V. Eliminating motion effects in medical images caused by physiological function
KR20140105103A (ko) 2013-02-21 2014-09-01 삼성전자주식회사 장기의 움직임을 추적하는 방법, 장치 및 의료 영상 시스템
CN103584847B (zh) 2013-11-06 2015-04-22 中国人民解放军第三军医大学 一种非接触磁感应心率和呼吸率同步检测方法及系统
JP2015159934A (ja) 2014-02-27 2015-09-07 セイコーエプソン株式会社 超音波計測装置及び超音波計測方法
CN103948401A (zh) 2014-05-20 2014-07-30 夏云 一种便携式肺功能仪器及肺功能检测方法
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
US20170281769A1 (en) 2014-09-03 2017-10-05 Medimmune Limited STABLE ANTI-IL-4Ra FORMULATION
CN104840218B (zh) 2015-06-09 2018-08-10 联想(北京)有限公司 一种呼吸速率的测量方法及电子设备
GB201519985D0 (en) 2015-11-12 2015-12-30 Respinor As Ultrasonic method and apparatus for respiration monitoring
AU2017256786B2 (en) 2016-04-29 2024-06-13 Horizon Therapeutics Ireland Dac Binding molecules specific for FcγGamma RIIA and uses thereof
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
WO2020061159A1 (fr) 2018-09-20 2020-03-26 Vanderbilt University Anticorps humains contre le virus zika
BR112022015374A2 (pt) 2020-02-03 2022-10-11 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
JP2023519105A (ja) 2020-02-11 2023-05-10 ヴァンダービルト ユニバーシティ 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）に対するヒトモノクローナル抗体
EP4245373A3 (fr) 2020-02-26 2023-12-20 VIR Biotechnology, Inc. Anticorps contre le sars-cov-2
WO2021183195A1 (fr) 2020-03-09 2021-09-16 1.Abcellera Biologics Inc. Anticorps anti-coronavirus et méthodes d'utilisation
US11053304B1 (en) 2020-03-23 2021-07-06 Centivax, Inc. Anti-SARS-Cov-2 antibodies derived from 6nb6
JP2023518849A (ja) 2020-03-26 2023-05-08 バンダービルト・ユニバーシティ 重症急性呼吸器症候群コロナウイルス２（ＳＡＲＳ－ＣｏＶ－２）に対するヒトモノクローナル抗体
JP7116256B1 (ja) 2020-04-02 2022-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体および抗原結合断片
WO2021203053A1 (fr) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunothérapie ciblant une région conservée dans des coronavirus sras
US11634477B2 (en) 2020-04-28 2023-04-25 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
US11919944B2 (en) * 2020-05-11 2024-03-05 Augmenta Biosciences, Inc. Antibodies for SARS-CoV-2 and uses thereof
CA3182150A1 (fr) 2020-05-17 2021-11-25 Astrazeneca Uk Limited Anticorps sars-cov-2 et procedes de selection et d'utilisation de ceux-ci
CA3187008A1 (fr) 2020-07-27 2022-02-03 Paul R. Hinton Molecules de liaison a un coronavirus multimeriques et leurs utilisations
IL300257A (en) 2020-08-10 2023-03-01 Astrazeneca Uk Ltd SARS-COV-2 antibodies for the treatment and prevention of COVID-19
KR20220020228A (ko) 2020-08-11 2022-02-18 (주)셀트리온 안정한 약제학적 제제
EP4288152A2 (fr) * 2021-02-04 2023-12-13 RQ Biotechnology Limited Anticorps
TW202342095A (zh) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 用於治療和預防ｃｏｖｉｄ—１９之組成物
JP2024544936A (ja) 2021-11-12 2024-12-05 アールキュー・バイオテクノロジー・リミテッド 組成物

Also Published As

Publication number Publication date
RS66591B1 (sr) 2025-04-30
LT4230650T (lt) 2025-03-10
EP4230650B1 (fr) 2024-11-13
SMT202500056T1 (it) 2025-03-12
PL4230650T3 (pl) 2025-04-28
HUE070285T2 (hu) 2025-05-28
WO2023156636A1 (fr) 2023-08-24
CL2024002462A1 (es) 2025-01-24
EP4230650A1 (fr) 2023-08-23
AR128564A1 (es) 2024-05-22
US20240376178A1 (en) 2024-11-14
FI4230650T3 (fi) 2025-02-12
SI4230650T1 (sl) 2025-06-30
PT4230650T (pt) 2025-02-13
TW202342510A (zh) 2023-11-01
US12030927B2 (en) 2024-07-09
ES3012638T3 (en) 2025-04-09
US20230265170A1 (en) 2023-08-24
HRP20250103T1 (hr) 2025-03-28
DK4230650T3 (da) 2025-02-10

Similar Documents

Publication Publication Date Title
MA61946B1 (fr) Anticorps capables de se lier à la protéine spike du coronavirus sars-cov-2
MA54405B1 (fr) Anticorps de la glycoprotéine de spicule anti-sras-cov-2 et fragments de liaison à l'antigène
MA31886B1 (fr) Anticorps anti-hepcidine et utilisations de ceux-ci
MA30041B1 (fr) Immunoglobulines
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
WO2022167816A3 (fr) Anticorps
CA3156451A1 (fr) Anticorps ayant une specificite pour la nectine -4 et leurs utilisations
MA54261B1 (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
MA45125B1 (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
MA33381B1 (fr) Proteine de liaison a il-13
PH12021552334A1 (en) Antibodies to pyroglutamate amyloid-㟠and uses thereof
MA62173B1 (fr) Formulations d'anticorps anti-rankl humains et leurs procédés d'utilisation
MA30337B1 (fr) Anticorps
MA30163B1 (fr) Anticorps monoclonaux specifiques pour a beta 1-42 ayant des proprietes therapeutiques
MA32725B1 (fr) Anticorps contre l'il 17 humaine et utilisations associees
MA28289A1 (fr) Immunoglobulines
WO2004024097A8 (fr) Compositions et methodes de traitement de maladies de nature immune
MXPA05010914A (es) Metodo de tratamiento de la enfermedad de alzheimer.
MA58646A1 (fr) Tubulysines et conjugués tubulysines-protéines
MA53765A1 (fr) Tubulysines et conjugués tubulysines-protéines
MA54975A1 (fr) Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation
MA37670A1 (fr) Anticorps anti-transglutaminase 2
EP4255385A4 (fr) Composition(s) antigénique(s) et méthodes(s) d'utilisation contrepour la prévention et/ou le traitement d'une infection et/ou de maladies
MA55872A (fr) Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires